GLP-1 Drugs in 2026: 7 Conditions Beyond Weight Loss
What Are GLP-1 Drugs Really Used For in 2026? 7 Conditions Beyond Weight Loss
By Ronald Kapper| Last updated: October 4, 2026Ask most people what GLP-1 drugs are for and they'll say weight loss. That was the headline for years, but it no longer describes the whole picture. In 2026, GLP-1 medications such as Ozempic, Wegovy and Zepbound are used, studied, and in some cases formally approved for conditions that have little to do with the number on the scale.
One recent overview notes the class now spans ten marketed products and six approved indications: type 2 diabetes, obesity or overweight, established cardiovascular disease, chronic kidney disease, MASH (a liver condition), and obstructive sleep apnea. The field keeps moving too. In December 2025 the FDA approved oral Wegovy 25 mg, the first oral GLP-1 for weight loss, and it also carries a heart-risk indication. medscapeprimetherapeutics
This guide covers seven conditions where GLP-1 drugs are being used or tested beyond weight loss. It separates what is approved from what is promising, and from what has failed. That distinction matters, because not every headline holds up.
What Are GLP-1 Drugs, and How Do They Work?
GLP-1 stands for glucagon-like peptide-1, a gut hormone that helps regulate blood sugar and appetite. GLP-1 receptor agonists mimic that hormone. They help the pancreas release insulin when glucose is high, slow stomach emptying, and signal fullness to the brain. Tirzepatide (Zepbound, Mounjaro) also mimics a second hormone, GIP.
Two points cause confusion. First, brand names map to specific uses. Ozempic and Wegovy contain the same molecule, semaglutide, but at different doses and with different labels. Second, "approved" has a precise meaning. A drug is only approved for the conditions on its label, so a promising trial result is not an approval.
1. Heart Attack and Stroke Prevention
The strongest evidence outside weight loss is in cardiovascular protection. The landmark SELECT trial found that Wegovy 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity. It enrolled 17,604 people aged 45 or older with established cardiovascular disease and no history of diabetes. You can read a summary from Managed Healthcare Executive. managedhealthcareexecutive
That result led to a cardiovascular risk-reduction indication for Wegovy. The pill form of Wegovy also carries this indication for adults with overweight or obesity and established heart disease. The benefit appears to go beyond what weight loss alone would explain, though researchers are still working out the mechanisms. Candidates are reduced inflammation, better blood pressure, and improved metabolic health. primetherapeutics
Status: Approved (Wegovy), for people with overweight or obesity and existing cardiovascular disease.
2. Chronic Kidney Disease in Type 2 Diabetes
Kidney disease affects roughly 40% of people with type 2 diabetes, so this finding matters. In the FLOW trial, researchers followed 3,533 patients with both type 2 diabetes and chronic kidney disease. Those taking semaglutide had a 24% lower risk of a primary-outcome event compared with controls. The trial was stopped early because the drug had clearly worked. pharmacist
The same trial reported an 18% reduction in major cardiovascular events and a 20% reduction in the risk of death from any cause. A 2026 analysis in JACC found the kidney benefit was consistent across patients with and without established cardiovascular disease or heart failure. The American College of Cardiology summary walks through the subgroup data. adameetingnewsacc
Status: Approved (Ozempic) for adults with type 2 diabetes and chronic kidney disease.
3. Fatty Liver Disease (MASH)
Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) is a progressive form of fatty liver disease that can lead to scarring and cirrhosis. Until recently, treatment options were very limited.
In the ESSENCE trial, fibrosis improved without worsening of MASH in 36.8% of patients on semaglutide versus 22.4% on placebo, and the FDA granted accelerated approval in August 2025. The UK regulator has also moved: the MHRA announced that Wegovy was approved to treat a form of liver disease. lifesciencedaily
Two caveats apply. The indication covers non-cirrhotic MASH with moderate to advanced fibrosis, and the Wegovy tablets do not carry it. "Accelerated approval" also means longer-term outcome data are still being collected. lifesciencedaily
Status: Approved (Wegovy injection), under accelerated approval.
4. Obstructive Sleep Apnea
Sleep apnea and obesity are closely linked, and tirzepatide has now been tested directly against it. Zepbound is the only FDA-approved GLP-1, and the only prescription medication of any kind, for obstructive sleep apnea (OSA). That second indication was added in December 2024. therxindexmodernweightscience
In the SURMOUNT-OSA program, tirzepatide reduced the apnea-hypopnea index, which measures how often breathing stops or is restricted each hour of sleep. The label specifies moderate-to-severe OSA in adults with obesity, and a sleep study is typically required for diagnosis. For a broader view of how this fits with the other indications, see the class overview on Medscape. onedaymd
One practical point: Wegovy, Ozempic and Mounjaro are not approved for sleep apnea. Although Mounjaro and Zepbound contain the same molecule, the prescribing indication matters, particularly for insurance coverage. therxindex
Status: Approved (Zepbound) for moderate-to-severe OSA in adults with obesity.
5. Knee Osteoarthritis Pain
Here the evidence is strong but the drug is not yet approved for the condition. The STEP 9 trial, published in the New England Journal of Medicine in October 2024, tested weekly semaglutide 2.4 mg in people with obesity and moderate knee osteoarthritis.
At week 68, the average change in the WOMAC pain score was −41.7 points with semaglutide and −27.5 points with placebo. The trial enrolled 407 participants. Body weight fell by 13.7% with semaglutide versus 3.2% with placebo. Details are available from HCPLive and the manufacturer's announcement. medicalrepublichcplive
Much of the benefit is probably mechanical, since less weight means less load on the joint. The authors noted the trial was not designed to investigate the mechanism. Novo Nordisk states that semaglutide is not approved for the treatment of knee osteoarthritis. Tolerability also mattered: 6.7% of the semaglutide group stopped treatment because of adverse events, versus 3.0% on placebo, mostly due to gastrointestinal problems. Semaglutide improves knee OA pain and function +2
Status: Promising phase 3 evidence, not approved for this use.
6. Alcohol Use Disorder
This is one of the most closely watched areas of research. Many people on GLP-1 drugs have reported drinking less, and trials are now testing whether that effect is real.
A phase 2 trial in the American Journal of Psychiatry randomized 50 adults with moderate to severe alcohol use disorder. Semaglutide did not significantly reduce laboratory-assessed craving or drinks per day compared with placebo, but it significantly reduced heavy drinking days. Participants also drank less on the days they did drink and reported greater reductions in everyday craving and alcohol-related problems. You can read the American Psychiatric Association's summary or the PubMed abstract. nihpsychiatry
This is early evidence. The authors concluded that continued development of semaglutide for alcohol use disorder is warranted. A smaller earlier trial, published in JAMA Psychiatry, pointed the same way but also called for larger studies. If you struggle with alcohol, evidence-based treatments already exist, and a doctor can discuss them with you. nih
Status: Investigational. Phase 2 results are encouraging, but larger trials are needed.
7. Alzheimer's Disease: The Cautionary Tale
Not every promising idea pans out, and Alzheimer's disease shows why. Earlier observational data suggested GLP-1 drugs might lower dementia risk, which generated enormous excitement. Then the two large phase 3 EVOKE trials reported their results.
The EVOKE and EVOKE+ trials were double-blind, placebo-controlled studies testing oral semaglutide in early-stage symptomatic Alzheimer's disease. They were published in The Lancet on March 19, 2026, and enrolled nearly 3,800 patients treated for two years. The outcome was clear. Semaglutide improved Alzheimer's-related biomarkers but did not reduce disease progression. Neurology Live and Clinical Trials Arena cover the full results. Oral Semaglutide Fails in Early Alzheimer Disease Trials - Neurology Advisor +2
Researchers have offered several interpretations. Many framed it not as proof that GLP-1 therapies are a dead end, but as a sign these agents may be tested too late in the disease course. The Alzheimer's Drug Discovery Foundation suggested the metabolic pathway may still hold promise, possibly within combination therapies. patientcareonline
For readers, the takeaway is that there is currently no evidence that GLP-1 drugs treat Alzheimer's disease. Be wary of clinics or influencers who suggest otherwise.
Status: Phase 3 trials failed. Not a treatment for Alzheimer's.
The Evidence at a Glance
| Condition | Status in 2026 | Key drug |
|---|---|---|
| Heart attack and stroke prevention | Approved | Wegovy |
| Chronic kidney disease (with type 2 diabetes) | Approved | Ozempic |
| MASH (liver disease) | Approved (accelerated) | Wegovy injection |
| Obstructive sleep apnea | Approved | Zepbound |
| Knee osteoarthritis pain | Not approved; strong phase 3 data | Semaglutide 2.4 mg |
| Alcohol use disorder | Investigational | Semaglutide |
| Alzheimer's disease | Phase 3 trials failed | Oral semaglutide |
Important Cautions Before Considering a GLP-1
Even with strong evidence, these drugs are not for everyone. Gastrointestinal side effects such as nausea and diarrhea are common, and they are the main reason people stop treatment. These medications are meant for specific medical situations, and a prescriber should weigh your history, other medications and goals. They are not a general wellness product.
Cost and access also shape real-world use. Coverage often depends on the indication, which is why the diagnosis on your prescription matters. If a clinic offers a GLP-1 for a condition outside its labeled use, ask what the evidence is and what the risks are.
Frequently Asked Questions
Are GLP-1 drugs only for weight loss? No. Beyond weight management, GLP-1 and related drugs are approved for type 2 diabetes, reducing cardiovascular events, chronic kidney disease in type 2 diabetes, MASH, and obstructive sleep apnea, depending on the specific drug.
Which GLP-1 is approved for sleep apnea? Only Zepbound (tirzepatide) is approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Wegovy and Ozempic are not.
Do GLP-1 drugs protect the heart? In the SELECT trial, Wegovy reduced major cardiovascular events by 20% in adults with overweight or obesity and existing cardiovascular disease. The benefit was shown in that population, not in everyone.
Can Ozempic or Wegovy treat Alzheimer's disease? No. Two large phase 3 trials of oral semaglutide found no slowing of disease progression in early Alzheimer's disease, despite changes in biomarkers.
Is Ozempic approved for alcohol addiction? No. Early trials show reductions in heavy drinking, but alcohol use disorder is not an approved use, and larger trials are still needed.
What is the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is approved for type 2 diabetes and related kidney and cardiovascular uses. Wegovy is approved for weight management, cardiovascular risk reduction, and MASH. Doses and labels differ.
Is there a GLP-1 pill? Yes. Oral Wegovy 25 mg was approved in December 2025 for weight management and for cardiovascular risk reduction in adults with heart disease and overweight or obesity.
The Bottom Line
In 2026, GLP-1 drugs are best understood as metabolic medicines with effects across the heart, kidneys, liver, airway and possibly the brain's reward system. The strongest evidence supports cardiovascular protection, kidney protection in type 2 diabetes, MASH, and sleep apnea. Knee osteoarthritis and alcohol use disorder look promising but unproven, and Alzheimer's disease serves as a reminder that biological plausibility is not clinical proof.
If you're considering a GLP-1 for any reason, talk to a qualified healthcare professional about whether the evidence applies to you.
Disclaimer: This article is for general information only and is not medical advice. Consult a licensed clinician before starting, stopping, or changing any medication.